Antimicrobial Susceptibility Pattern of Clinical Isolates of Escherichia coli and Proteus mirabilis Using Cefepime in Ogbomoso, Nigeria.

Authors

  • Oladipo E Kolawole
  • Amao J. A.
  • Omomowo I. O.
  • Agboola J. O.
  • Afolabi A. Y.
  • Akinade B. S.

Keywords:

Cefepime, LAUTECH, Ogbomoso, Escherichia coli, Proteus mirabilis, Sensitivity

Abstract

The challenge of Cefepime resistance in developing countries is substantial and likely to grow. Emergence of Cefepime-resistant bacteria has increased and management

References

Paterson D.L. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med. 2006; 119 (Suppl 1):S20-8.

Pallecchi, L., Malossi, M., Mantella, A., Gotuzzo, E., Trigoso, C., Bartoloni, A., Paradisi, F., Kronvall, G., and Rossolini, G. M.

Luzzaro F., Vigano E.F., Fossati D., Grossi A., Sala A., Sturla C.Prevalence and drug

susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis.2002;21(12):849-55.

Rozalski A., Sidorczyk Z., Kotelko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev. 1997; 61:65

Daza R., Gutierrez J., Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents. 2001; 18:211

Lindsay E., Nicolle M.D. Resistant pathogens in urinary tract infections. J Am Geriatr Soc. 2002; 50:230

Pagani L., Migliavacca R., Pallecchi L., Matti C., Giacobone E., Amicosante G., Romero E. Emerging extended-spectrum beta-lactamases in Proteus mirabilis. J Clin Microbiol .2002;40: 1549

Karlowsky J.A., Kelly L.J., Thornsberry C., Jones M.E., Sahm D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother .2002; 46:2540

Khan A.U., Musharra F.A. Plasmid-mediated multiple antibiotic resistance in Proteus mirabilis isolated from patients with urinary tract infection.Med Sci Monit 2004;10: 598

Rodriguez-Bano J., Navarro M.D., Romero L., Martinez-Martinez L., Muniain M.A., Perea E.J., Perez-Cano R. and Pascual A. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase producing Escherichia coli in non-hospitalized patients. J Clin Microbiol 2004, 42:1089-94.

Paterson D.L. and Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-86.

Lowy, F.D.

Stamm, W.E. Urinary tract Infection. In Clinical Infectious Diseases: A practical approach, Root K (ed). Oxford Universitry Press Inc, New York, 1999. P 649 - 656

De Champs C., Bonnet R., Sint D., Chanal C. and Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: A two year survey. J Antimicrob Chemoth. 2009; 45: 537 - 539

Watanakunakorn C., Pernis S.C. Protues mirabilis bacteremia: a review of 176 cases during 1980

Grahnquist L., Lundberg B., Tullus K. Neonatal Proteus meningoencephalitis. Case report. Acta Pathol, Microbiol. Immunol Scand. 1992; 100: 734

Isenstein D.,Honing E. Proteus vulgaris empyema and increased pleural fluid pH. Chest 1990; 95: 511

Max A.C., Harsthorwe M.F., Stull M.A., Truwt C.L. Case report 496: intraosseous gas in Proteus mirabilis osteomyelitis complicating bone infarcts in sickle cell disease. Skeletal Radiol. 1988; 17:510

Pfaller M.A., Jones R.N., Doern G.V., Kugler K..The Sentry Participants Group: Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada,1997). Antimicrob Agents Chemother1998; 42: 1762

Pechere J.C. and Vladoianu I.R.: Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother 1992; 29: 563

Jolt JG, Krieg NR, Sneath PHA, Stanley JT, Williams ST Bergey

Cheesbrough M. District Laboratory Practice in Tropical Countries. Cambridge University Press. 2006;434.

Oyeleke S.B., Manga S.B. Essentials of Laboratory Practicals in Microbiology Tobest publisher. Minna. Nigeria. 2008;36-75.

Kader A.A. and Kumar A. Prevalence antimicrobial susceptibility of extended- spectrum beta-lactamase

Pallecchi L., Bartoloni A., Fiorelli, C.,Mantella, A.,DiMaggio, T.,Gamboa, H.,Gotuzzo, E., Kronvall, G., Paradisi, F., and Rossolini, G.M.

Newman M.J., Frimpong E., Asamoah

Yah S.C., Egbanfona N.O., Oranusi S. and Abono A.M. Wide spread plasmid resistance genes among Proteus species in diabetic wounds of patients in Ahmadu Bello University Teaching Hospital (ABUTH) Zaria. Afr J. Biotechnol 2001 6(15): 1757 - 1762

Moreno E., Prats G., Sabate M., Perez T., Johnson J.R., Andreu A. Quinolone, fluoroquinolone and trimethoprim/sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli. J Antimicrob Chemother (2006) 57:204

Wioletta A. B. , Elzbieta Z, Pawel Pi and Wieslaw K. Comparison of antibiotic resistance patterns in collections of Escherichia coli and Proteus mirabilis uropathogenic strains, Molecular Biology Reports,(2013).

Downloads

Published

2014-07-25

How to Cite

Kolawole, O. E., A., A. J., O., O. I., O., A. J., Y., A. A., & S., A. B. (2014). Antimicrobial Susceptibility Pattern of Clinical Isolates of Escherichia coli and Proteus mirabilis Using Cefepime in Ogbomoso, Nigeria. International Journal of Sciences: Basic and Applied Research (IJSBAR), 17(1), 202–209. Retrieved from https://gssrr.org/index.php/JournalOfBasicAndApplied/article/view/2369

Issue

Vol. 17 No. 1 (2014)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.